239 related articles for article (PubMed ID: 25810233)
1. Cost-effectiveness of becaplermin gel on wound healing of diabetic foot ulcers.
Gilligan AM; Waycaster CR; Motley TA
Wound Repair Regen; 2015; 23(3):353-60. PubMed ID: 25810233
[TBL] [Abstract][Full Text] [Related]
2. Cost-Effectiveness of Becaplermin Gel on Diabetic Foot Ulcer HealingChanges in Wound Surface Area.
Waycaster CR; Gilligan AM; Motley TA
J Am Podiatr Med Assoc; 2016 Jul; 106(4):273-82. PubMed ID: 27049838
[TBL] [Abstract][Full Text] [Related]
3. The cost-effectiveness of treating diabetic lower extremity ulcers with becaplermin (Regranex): a core model with an application using Swedish cost data.
Persson U; Willis M; Odegaard K; Apelqvist J
Value Health; 2000; 3 Suppl 1():39-46. PubMed ID: 16464208
[TBL] [Abstract][Full Text] [Related]
4. Cost Effectiveness of Becaplermin Gel on Wound Closure for the Treatment of Pressure Injuries.
Gilligan AM; Waycaster CR; Milne CT
Wounds; 2018 Jun; 30(6):197-204. PubMed ID: 29809161
[TBL] [Abstract][Full Text] [Related]
5. Cost effectiveness of Becaplermin in the treatment of diabetic foot ulcers in four European countries.
Ghatnekar O; Persson U; Willis M; Odegaard K
Pharmacoeconomics; 2001; 19(7):767-78. PubMed ID: 11548912
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of Novel Macrophage-Regulating Treatment for Wound Healing in Patients With Diabetic Foot Ulcers From the Taiwan Health Care Sector Perspective.
Su HY; Yang CY; Ou HT; Chen SG; Chen JC; Ho HJ; Kuo S
JAMA Netw Open; 2023 Jan; 6(1):e2250639. PubMed ID: 36633847
[TBL] [Abstract][Full Text] [Related]
7. The cost effectiveness of Apligraf treatment of diabetic foot ulcers.
Redekop WK; McDonnell J; Verboom P; Lovas K; Kalo Z
Pharmacoeconomics; 2003; 21(16):1171-83. PubMed ID: 14594438
[TBL] [Abstract][Full Text] [Related]
8. Cost-effective management of recalcitrant diabetic foot ulcers.
Albert S
Clin Podiatr Med Surg; 2002 Oct; 19(4):483-91. PubMed ID: 12471856
[TBL] [Abstract][Full Text] [Related]
9. Analysis of patient cost for recombinant human platelet-derived growth factor therapy as the first-line treatment of the insured patient with a diabetic foot ulcer.
Lantis JC; Boone D; Gendics C; Todd G
Adv Skin Wound Care; 2009 Apr; 22(4):167-71. PubMed ID: 19325276
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of becaplermin for nonhealing neuropathic diabetic foot ulcers.
Sibbald RG; Torrance G; Hux M; Attard C; Milkovich N
Ostomy Wound Manage; 2003 Nov; 49(11):76-84. PubMed ID: 14652415
[TBL] [Abstract][Full Text] [Related]
11. Diabetic foot ulcers treated with becaplermin and TheraGauze, a moisture-controlling smart dressing: a randomized, multicenter, prospective analysis.
Landsman A; Agnew P; Parish L; Joseph R; Galiano RD
J Am Podiatr Med Assoc; 2010; 100(3):155-60. PubMed ID: 20479444
[TBL] [Abstract][Full Text] [Related]
12. Healing and preventing the diabetic foot wound: where technology, economics and common sense converge.
Armstrong DG
Indian J Med Sci; 2007 Jun; 61(6):324-5. PubMed ID: 17558094
[No Abstract] [Full Text] [Related]
13. Becaplermin gel in the treatment of diabetic neuropathic foot ulcers.
Papanas N; Maltezos E
Clin Interv Aging; 2008; 3(2):233-40. PubMed ID: 18686746
[TBL] [Abstract][Full Text] [Related]
14. Treatment options for diabetic neuropathic foot ulcers: a cost-effectiveness analysis.
Kantor J; Margolis DJ
Dermatol Surg; 2001 Apr; 27(4):347-51. PubMed ID: 11298704
[TBL] [Abstract][Full Text] [Related]
15. Economic outcomes among Medicare patients receiving bioengineered cellular technologies for treatment of diabetic foot ulcers.
Rice JB; Desai U; Ristovska L; Cummings AK; Birnbaum HG; Skornicki M; Margolis DJ; Parsons NB
J Med Econ; 2015; 18(8):586-95. PubMed ID: 25786331
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of treating deep diabetic foot ulcers with Promogran in four European countries.
Ghatnekar O; Willis M; Persson U
J Wound Care; 2002 Feb; 11(2):70-4. PubMed ID: 11901743
[TBL] [Abstract][Full Text] [Related]
17. Immunomodulatory role of Tinospora cordifolia as an adjuvant in surgical treatment of diabetic foot ulcers: a prospective randomized controlled study.
Purandare H; Supe A
Indian J Med Sci; 2007 Jun; 61(6):347-55. PubMed ID: 17558098
[TBL] [Abstract][Full Text] [Related]
18. Recombinant human platelet-derived growth factor-BB (becaplermin) for healing chronic lower extremity diabetic ulcers: an open-label clinical evaluation of efficacy.
Embil JM; Papp K; Sibbald G; Tousignant J; Smiell JM; Wong B; Lau CY
Wound Repair Regen; 2000; 8(3):162-8. PubMed ID: 10886806
[TBL] [Abstract][Full Text] [Related]
19. Clinical efficacy of becaplermin (rhPDGF-BB) gel. Becaplermin Gel Studies Group.
Wieman TJ
Am J Surg; 1998 Aug; 176(2A Suppl):74S-79S. PubMed ID: 9777976
[TBL] [Abstract][Full Text] [Related]
20. Becaplermin gel (PDGF-BB) as topical wound therapy. Plastic Surgery Educational Foundation DATA Committee.
Ladin D
Plast Reconstr Surg; 2000 Mar; 105(3):1230-1. PubMed ID: 10724287
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
